Navigation Links
IDM Pharma Reports First Quarter Financial Results
Date:5/8/2008

oring. The Company supported the COG in this effort.

The Company expects to receive a final opinion from the CHMP in the third quarter and a final decision from the European Commission in the fourth quarter of 2008.

As previously announced, in the United States the Company continues to work with the COG as well as external experts and advisors to gather patient follow up data from the Phase 3 clinical trial of L-MTP-PE and to respond to other questions in the non-approvable letter the Company received from the U.S. Food and Drug Administration (FDA). The Company expects to submit the amended NDA in the fourth quarter of 2008.

L-MTP-PE was granted orphan drug status in the United States in 2001 and in Europe in 2004. In Europe, the MAA was filed in November 2006 and in the U.S., the NDA was submitted to FDA in October 2006 and was accepted for review in December 2006.

About IDM Pharma

IDM Pharma is focused on the development of innovative cancer products that either destroy cancer cells by activating the immune system or prevent tumor recurrence by triggering a specific adaptive immune response. IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of its innovative products to address the needs of patients and the physicians who treat these patients.

For more information about the company and its products, visit http://www.idm-pharma.com.

Forward-Looking Statements

This press release includes forward-looking statements that reflect management's current views of future events including statements regarding the timeframe in which the Company's cash will be sufficient to meet planned operations, the Company's plans to address the remaining questions with respect to the MAA during the clock-stop granted by the CHMP, and the expected timing of a final opinion from the CHMP and of a final regulatory decision regarding the MAA
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Vion Pharmaceuticals to Appeal Nasdaq Delisting
2. Amneal Pharmaceuticals Receives US FDA Approval for Three Generic Prescription Drugs; Two Using New FDA Electronic Filing Format
3. Patients, Doctors, Pharmacists Praise Bipartisan House Resolution on Compounded Hormones Containing Estriol
4. AMDL Signs Letter of Intent to Purchase a China Based Pharmaceutical Distribution Company
5. Par Pharmaceutical Acquires Spectrum Pharmaceuticals Interest In Sumatriptan Injection
6. ISTA Pharmaceuticals to Present at the Bank of America 2008 Health Care Conference
7. WuXi PharmaTech Announces Postponement of Proposed Follow-on Offering
8. Cadient Group Continues Winning Streak; Receives Multiple Honors at 2008 Pharmaceutical Advertising and Marketing Excellence Awards
9. Medpace Director of Clinical Pharmacology, Jim Wei, MD, PhD, Embarks on a Regulatory Policy Speaking Tour in China in May
10. Alseres Pharmaceuticals, Inc. to Present at The Neurotech Industry Investing & Partnering Conference
11. Par Pharmaceutical to Host First Quarter 2008 Earnings Conference Call on May 9 at 9:00 AM
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Medical travel facilitator Companion Global Healthcare ... Rico into its network of international hospitals that ... those at mainland U.S. facilities. ,, The announcement ... assistance and preferred pricing for its individual clients ... either HIMA San Pablo Bayamon or HIMA San ...
(Date:12/16/2009)... a random sampling of wood pallets used to ... numerous pallets tested positive for Listeria and abnormally ... health hazards for consumers. The new data ... conducted in the Washington-Baltimore area, further illustrating the ... food supply from wood pallets. ,, The new ...
(Date:12/16/2009)... Medicine,s (BUSM) Pulmonary Center has received a two-year ... and Blood Institute to derive stem cells and ... , Darrell Kotton, MD, associate professor of medicine ... professor of medicine, are the principal investigators of ... lead a multicenter investigative team of five Boston ...
(Date:12/16/2009)... Growth Fueled By Customer Satisfaction, New Partners and Global Market Expansion ... ... Kampyle , a provider of Feedback Analytics to Web sites ... with the addition of 25,000 new customers. Since its launch ... forms in more than 60 languages, and amassed more than 30,000 ...
(Date:12/16/2009)... For ages, people from around the world have visited ... waters have a reputation that dates back over 2000 ... Now, with the introduction of two bath salt lines ... legendary benefits of Dead Sea salt in their own ... Dead Sea salt and essential oils - but no ...
Breaking Medicine News(10 mins):Health News:Hospitals in Puerto Rico Join Companion Global Healthcare's Network 2Health News:New Tests Confirm Wood Pallets Harbor Deadly Food Poisoning Bacteria 2Health News:New Tests Confirm Wood Pallets Harbor Deadly Food Poisoning Bacteria 3Health News:New Tests Confirm Wood Pallets Harbor Deadly Food Poisoning Bacteria 4Health News:Boston University School of Medicine's pulmonary center receives $1.4 million grant 2Health News:Kampyle Experiences Record Growth in 2009 with 25,000 New Customers 2Health News:Kampyle Experiences Record Growth in 2009 with 25,000 New Customers 3Health News:Kampyle Experiences Record Growth in 2009 with 25,000 New Customers 4Health News:Kampyle Experiences Record Growth in 2009 with 25,000 New Customers 5Health News:SaltWorks Launches Two All-Natural Bath Salt Lines Featuring Therapeutic Salt from the Dead Sea 2Health News:SaltWorks Launches Two All-Natural Bath Salt Lines Featuring Therapeutic Salt from the Dead Sea 3
... symptoms of hysteria are often ticked off, by ... ailment.// However, researchers from Sunnybrook Health Sciences Centre, disagree ... or emotional instability. ,Brain scans helped to ... tissue in three women with hysteria. Technically, hysteria ...
... seven pounds with a diet of big meals and sweets ... a pound or two during// the holidays, according to a ... slight weight gain, if left intact, can accumulate yearly and ... pound or two and not working it off, even with ...
... has come up with another project. This scheme named "Prevention ... cost Rs 342.81-crores. ,The Global Fund aids the ... also be spent for reducing the transmission of HIV to ... antiretroviral therapy to those already infected. ,There is ...
... championship for under-14 is being conducted at the Auckland Aquatic ... after participating in a game at the West Wave Aquatic ... respiratory problems and had to be admitted in the hospital. ... “ The council is deeply concerned by what had occurred ...
... Till date we associated fat in the diet with ... leading to inflammatory conditions such as asthma. ,News ... Sydney discovered a link between fat consumed in a ... connection can lead to the formation of asthma and ...
... for sick leave the following day due to the hang ... Centre for Education and Training on Addiction at Flinders University ... year the estimated loss due alcohol related abseentism is $473 ... 2.6 million work days. ,He claims, "Low-risk drinkers and ...
Other Medicine News:Health News:Even Slight Weight Gain Can Set Stage for Obesity and Health Risks 2
(Date:12/16/2009)... HARTFORD, Conn., Dec. 16 CareCentrix, ... health benefits management services, announced today that it ... a Washington, DC-based health care accrediting organization that ... URAC standards guarantee that only appropriately trained, qualified ... process, that a reasonable and timely appeals process ...
(Date:12/16/2009)... Biovista Inc.,today announced that it was awarded the ... 2009 New England Venture Summit, held on December ... edge private companies,driving the future of innovation, was ... privately held companies that play a leading role ... sectors. , "We are ...
(Date:12/16/2009)... Dec. 16 GlaxoSmithKline plc [GSK] (NYSE: ... announced an exclusive licensing agreement in the United ... of NB-001, a novel, patented compound representing the ... Developed by NanoBio, NB-001 provides significant antimicrobial activity ... herpes labialis . ,, Cold sores are ...
Breaking Medicine Technology:CareCentrix Receives URAC Health Utilization Management Accreditation 2Biovista Inc. Named Top Innovator in Life Sciences 2GlaxoSmithKline and NanoBio Announce OTC Licensing Agreement for Cold Sore Treatment 2AACR NCI and EORTC to host Molecular Targets and Cancer Therapeutics International Conference 10655 1Retirement Brings Most a Big Health Boost 60954 1Retirement Brings Most a Big Health Boost 60954 2Retirement Brings Most a Big Health Boost 60954 3Natural Nutrition Acquires App Tech Global Inc 60952 1
... 2007 /PRNewswire/ -- Interim results from,a multicenter ... CellCept(R) (mycophenolate mofetil) were presented,at the American ... (STN) trials in kidney and liver transplant ... kidneys. , As transplant patients are living ...
... 2 BPD Clinical Data Selected and ... Chrysalis Aerosol-Generator Technology,Demonstrates Optimal Functional Activity ... (PRIME NEWSWIRE) -- Discovery,Laboratories, Inc. (Nasdaq:DSCO) ... Phase 2 clinical trial of Surfaxin(r),(lucinactant ...
Other Medicine Technology:Early Results of the CellCept Spare the Nephron Study Examine,Kidney Function 2Early Results of the CellCept Spare the Nephron Study Examine,Kidney Function 3Early Results of the CellCept Spare the Nephron Study Examine,Kidney Function 4Early Results of the CellCept Spare the Nephron Study Examine,Kidney Function 5Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting 2Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting 3Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting 4Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting 5Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting 6Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting 7
... breadth of infectious disease ELISA products make ... standard assay protocols for faster integration into ... products provide increased reliability and run-to-run consistency. ... detection assays for a wide range of ...
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... infectious disease ELISA products make us a ... protocols for faster integration into the busy ... increased reliability and run-to-run consistency. Our Infectious ... for a wide range of serological assays ...
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
Medicine Products: